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Background: Emergency department (ED) patients with venous thromboembolism (VTE) are 
eventually treated with a standard dose of warfarin despite the fact that a number of patients are 
known to be sensitive to warfarin and may experience supra-therapeutic INRs and adverse bleeding 
events. Pharmacogenetics is an emerging field of medical practice that seeks to improve drug safety 
and efficacy in an individual patient by tailoring treatment to the patient’s known genetic makeup. 
Objective: To identify patients with risk for warfarin sensitivity among an ED population with VTE 
and to assess if the warfarin sensitivity mutations were of significant enough prevalence to be of 
clinical significance in customizing treatment of VTE. We sought in a pilot study to identify if testing 
for common CYP2C9 and VKORC1 single nucleotide polymorphisms (SNPs) in patients who were 
likely to begin warfarin treatment was feasible in an ED setting. 
Methods: A prospective study that identified and enrolled patients presenting to our ED with high 
clinical suspicion of VTE. Those with high clinical suspicion of VTE were defined as those who had a 
Doppler ultrasound or computed tomography pulmonary angiography (CTPA) ordered by the primary 
emergency physician. Blood was taken and processed to ascertain the following SNPs: CYP2C9*2, 
CYP2C9*3, and VKORC1 3673. 
Results: Of the 194 patients enrolled, 132 (68.0%) had at least one known warfarin sensitivity 
mutation and 114 (58.8%) had the most clinically significant VKORC1 3673 mutation. 
Conclusion: A majority of our patients had at least one mutation associated with the atypical 
metabolism of warfarin. Over half of our population had the most clinically significant VKORC1 
3673 mutation. They would likely benefit from individualized warfarin dosing if ever needing 
anticoagulation. Our initial pilot study shows that allele frequencies of target warfarin sensitivity 
SNPs in our patient population are frequent enough to make initiation of personalized warfarin 
dosing feasible. [West J Emerg Med. 2011;12(1):11-16.]
INTRODUCTION 
Warfarin sodium is the most popular coumarin 
anticoagulant used worldwide. In 2004, 31 million dispensed 
outpatient prescriptions were written for warfarin in the 
United States (U.S.) alone. This number represents a 45% 
growth in the number of warfarin prescription from only six 
years prior and the number continues to rise.1 Warfarin 
unfortunately also boasts one of the highest risk profiles for 
any drug on the market. Its extensive use, along with its high 
rate of adverse events, adds a significant amount of morbidity 
and mortality in the U.S. annually. Despite its drawbacks, 
warfarin remains standard treatment for venous 
thromboembolism (VTE) because it is effective and 
inexpensive. The typical emergency physician’s use of 
warfarin is limited to initiating therapy for the occasional 
low-risk VTE patient who will be treated as an outpatient, as Western Journal of Emergency Medicine  12  Volume XII, no. 1  :  February 2011
well as adjusting dosage in the setting of an abnormally high 
or low INR.  
The significant amount of morbidity and mortality 
attributed to warfarin has made it a favorite drug of focus for 
the growing pharmacogenetics movement. Pharmacogenetics 
is an emerging field of medical practice that seeks to improve 
drug safety and efficacy in an individual patient by tailoring 
pharmacologic treatment to the patient’s known genetic 
makeup. Pharmacogenetics will undoubtedly produce many 
novel applications in emergency medicine and personalized 
warfarin dosing is likely to be among the first. Were 
emergency clinicians better able to predict a patient’s 
individual response to warfarin treatment when initiating or 
adjusting therapy, the risk and incidence of adverse effects 
should be diminished. This knowledge may also serve to 
increase the proportion of patients with newly diagnosed VTE 
who are safe to initiate oral anticoagulation at home with close 
outpatient follow up instead of inpatient warfarin initiation.
The pharmacogenetic focus for warfarin has primarily 
been on two enzymes involved in its mechanism of action and 
metabolism: the Vitamin K epoxide reductase complex subunit 
1 (VKORC1) and the cytochrome P450 2C9 (CYP2C9) enzyme. 
We sought to identify in a pilot study if testing for common 
CYP2C9 and VKORC1 single nucleotide polymorphisms 
(SNPs) in patients who were likely to begin warfarin treatment 
was feasible in an emergency department (ED) setting. 
When researchers utilized VKORC1 mutations, CYP2C9*2, 
CYP2C9*3, and a number of demographics (age, body weight 
and concomitant medications) in a Swedish population, they 
were able to account for 50-60% of warfarin dose variability.2 
By adding knowledge of an individual’s Protein C SNPs 
they were able to increase the dose variation prediction to 
62%. Adding on a number of other additional SNPs of minor 
molecules involved in warfarin’s action only increased the 
prediction to 73%. This showed that while a better prediction 
of dose variation could be obtained by genotyping many 
additional SNPs, the majority of warfarin dose variation 
can be explained by simple patient demographics and the 
VKORC1, CYP2C9*2, and CYP2C9*3 mutations.3 As such, 
the VKORC1 3673 (1639G>A), CYP2C9*2 (430C>T), and 
CYP2C9*3 (1075A>C) SNPs served as the focus of our 
investigation. Little is known about the allele frequencies of 
CYP2C9*2, CYP2C9*3 and VKORC1 3673 in a Hispanic 
population; we also sought to investigate if the allele 
frequencies in our predominately Hispanic patient population 
were high enough to warrant testing for such mutations.
METHODS 
This study was an initial pilot study of feasibility. As such 
we conducted a cross-sectional study with convenience 
sampling of an ED population with suspected VTE. We chose 
to study a patient population with suspected thromboembolic 
disease because we believed VTE diagnosed in the ED would 
be the most likely time an emergency physician would initiate 
warfarin therapy. As our selected mutations involve a patient’s 
susceptibility to warfarin sensitivity and not to VTE 
susceptibility, we did not expect to see any difference in the 
mutation rates between those patients eventually diagnosed as 
VTE positive and those VTE negative. 
Our study design and protocol was approved by the 
University of Southern California Health Sciences 
Institutional Review Board. The authors have no conflicts of 
interest to report. Trained research assistants identified eligible 
patients in the LAC+USC Emergency Department and 
inpatient wards for enrollment. The enrollment time period 
was from April 2006 to July 2008. Our inclusion criteria were 
age ≥ 18, ability to give informed consent, in either English or 
Spanish, and having received an ultrasound of the lower 
extremities or computed tomography pulmonary angiogram 
(CTPA) ordered from the ED. Our only exclusion criterion 
was not satisfying all inclusion criteria.  
Trained research assistant obtained informed consent for 
patients willing to participate, using either English or Spanish 
documents and consent forms. The study participants were 
asked a brief focused medical history and to self-identify 
their ethnicity as White, Hispanic, Black, Asian or other. 
Blood samples were obtained for each participant. DNA 
extraction was accomplished using the Qiagen 96 DNA Blood 
Biorobotic Kit. Genotyping was done using the Taqman 5’ 
Nuclease Assay looking for the following polymorphisms: 
CYP2C9*2 (430C>T) (rs1799853), CYP2C9*3 (1075A>C) 
(rs1057910), VKORC1 3673 (1639 G>A) (rs9923231). For 
each polymorphic site, two oligonucleotide fluorogenic minor 
Table 1. Demographics.
Study Population (n=194)
Age
    18-29 15 7.7%
    30-49 77 39.7%
    50-69 86 44.3%
    >70 16 8.2%
Average age 50.2
Total 194 100.0%
Gender
    Male 96 49.5%
    Female 98 50.5%
Total 194 100.0%
Ethnicity
    Asian 6 3.1%
    Black 36 18.6%
    Hispanic 124 63.9%
    Caucasian 24 12.4%
    Other 4 2.1%
Total 194 100.0%
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groove binding probes were designed using Primer Express 
2.0 Software (Applied Biosystems).  We read and analyzed 
the fluorescence patterns of the PCR samples using an ABI 
7900HT Sequence Detection System and Sequence Detection 
Software (Applied Biosystems). For reporting purposes, the 
CYP2C9*2 and *3 haplotypes are often combined in the 
literature and written as *1/*1 (for wild type), *1/*2, *1/*3, 
*2/*2, *2/*3, and *3/*3.  
RESULTS
Of the 194 patients enrolled, 132 (68.0%) had at least one 
warfarin sensitivity mutation of either the CYP2C9 enzyme or 
VKORC1 receptor (Table 2). We had 20 patients (10.3%) with 
two mutations and two patients (1.0%) with all three 
mutations. For the most clinically significant VKORC1 3673 
(1639G>A), we had 114 patients (58.8%) with mutations, 86 
(44.3%) of whom were heterozygote variants (GA) and 28 
(14.4%) of whom were homozygote variants (AA). 
Our study also offered a unique opportunity to test the 
allele frequencies of a predominantly Hispanic cohort of 
patients. Approximately 64% (n=124) of our population 
self-identified as Hispanic. Calculated variant allele 
frequencies for our Hispanic cohort were: 5.73% for 
CYP2C9*2 T allele, 3.28% for CYP2C9*3 C allele, and 
46.64% for VKORC1 3673 A allele (Table 3).
DISCUSSION
In 2002 and again in 2004-2005, warfarin and insulin 
were the two most commonly identified medications 
associated with adverse events presenting to U.S. EDs.16-18 
From 1999-2003 there were an estimated 29,000 ED visits in 
the U.S. for warfarin bleeding complications alone. 
Throughout the 1990s and 2000s warfarin has continually 
been in the FDA’s Adverse Event Reporting System’s top 10 
most reported drugs.1 The frequency of “major bleeding” 
(leading to death or requiring hospitalization or transfusion) 
adverse effects for patients on warfarin varies by study but has 
been reported to be anywhere from 0-16%.19-21 From a survey 
of U.S. death certificates, anticoagulants were the most 
frequently mentioned drugs causing “adverse events in 
therapeutic use” in 2003 and 2004.  
The pharmacogenetic focus for warfarin on CYP2C9 and 
VKORC1 has been because these two enzymes are key to 
warfarin’s mechanism of action and metabolism. Normally, 
Vitamin K is recycled by the liver using the VKOR enzyme 
complex. This allows for the efficient use of Vitamin K and 
allows for sufficient stores of the reduced forms of the Vitamin. 
Reduced Vitamin K is the main cofactor used by gamma-
glutamyl carboxylase (GGCX) to activate Vitamin K-dependent 
proteins: factors II, VII, IX, and X and proteins C and S. 
Warfarin acts by blocking the VKORC subunit 1 (VKORC1), 
thereby preventing the recycling of Vitamin K. This leads to a 
depletion of the body’s Vitamin K stores and decreased 
activation of Vitamin K-dependent clotting factors. Inactivated 
Vitamin-K dependent proteins are eventually secreted from the 
body.3 Warfarin sodium, as administered, generally consists of a 
racemic mixture of the R-enantiomer and S-enantiomer of the 
drug. The S-form is 3-5 times more active than the R-form.22 
Table 2. Warfarin sensitivity single nucleotide polymorphisms 
(SNP).
    Homozygous wild type (CC) 167
    Heterozygous variant (CT) 25
    Homozygous variant (TT) 0
    Unknown (UU) 2
194
Variant allele (T) frequency 6.5%
    Homozygous wild type (AA) 172
    Heterozygous variant (AC) 17
    Homozygous variant (CC) 0
    Unknown (UU) 5
194
Variant allele (C) frequency 4.5%
    Homozygous wild type (GG) 67
    Heterozygous variant (GA) 86
    Homozygous variant (AA) 28
    Unknown (UU) 13
194
Variant allele (A) frequency 39.2%
Note: 132 patients of our sample size of 194 had mutations.  
Some of these 132 had multiple mutations (20 patients with 
2 mutations and 2 patients with all 3 mutations).  So in total 
we detected 156 mutations in our 132 patients [(110 patients 
x 1 mutation) + (20 patients x 2 mutations) + (2 patients x 3 
mutations) = 156 mutations].
Table 3. Allele frequencies by ethnicity. 
CYP2C9*2 
(T)
CYP2C9*3 
(C)
VKORC1 3673 
(A)
Hispanic Cohort 
(n=124)
5.7% 3.3% 46.6%
Reported in the 
Literature:
Asian4-6 0% 1.5 - 2.8% 89.9 - 91.4%
Black7,8 5.2% 1% 8.8 - 9.5%
Hispanic9-12 4.8 - 12% 3 - 6.0% 45%
White3,4,7,8,13-15 10.5 - 13.1% 5.8 – 8.4% 37.1 - 43%
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Once in the liver, S-warfarin is primarily metabolized by the 
cytochrome P450 2C9 (CYP2C9) enzyme.3 While other 
cytochrome P450 enzymes metabolize R-warfarin, since it is the 
less active form, these enzymes are not as clinically significant 
to the pharmacokinetics of warfarin.  
Numerous researchers have explained up to 50-60% of the 
variance in warfarin doses seen among patients, using the 
common VKORC1 and CYP2C9 SNPs and known 
environmental factors.2,14,15,23-28 Mutations in the VKORC1 
gene alone are reported to account for approximately 25-30% 
of warfarin dose variance.2,15,29 CYP2C9*3(1075A>C) 
mutation is a SNP substitution of a normal adenine with a 
cytosine at nucleotide position 1075 of the gene. This 
mutation severely impairs the CYP2C9 enzyme from 
hydroxylating s-warfarin, leading to a 27-fold decrease in 
enzyme efficiency and 71-97% reduced warfarin clearance.4,30 
The CYP2C9*3 mutation alone contributes approximately 
10-12% to warfarin dose variance.3,15,29,30 The 
CYP2C9*2(430C>T) mutation is a SNP substitution of a 
normal cytosine for thymine at nucleotide position 430 of the 
gene. This SNP also results in reduced warfarin metabolism, 
but only an approximate six-fold reduction in enzyme 
efficiency and 29-58% reduced warfarin clearance.4,31,32
The specific CYP2C9*2 SNP contributes only 2.5% to 
warfarin dose variance.2 However, many other CYP2C9 SNPs 
are in strong linkage disequilibrium with CYP2C9*2, and 
testing for the *2 SNP likely continues in the literature 
because it represents the best way to test for all the other SNPs 
in linkage disequilibrium with it. When researchers tested 55 
other CYP2C SNPs, only one added more to dose variation 
prediction than simply using CYP2C9*2 and CYP2C9*3 
alone.3 So, testing of the CYP2C9*2 and *3 SNPs remains a 
good way to approximate an individual’s CYP2C9 phenotype.
There are an increasingly large number of newly 
discovered mutations of the VKORC1 receptor. One of the 
most commonly studied mutations is the VKORC1 
3673(1639G>A). This SNP substitutes a normal guanine with 
an adenine at nucleotide position 1639 of the gene. Because 
this SNP has been found to be in strong linkage disequilibrium 
(r2>0.9) to a number of other VKORC1 SNPs significantly 
associated with warfarin dosing (381, 6484, 6853, and 7566) it 
is a good candidate for testing all of these mutations.29 It is 
believed that individuals with mutation VKORC1 enzymes 
have lower baseline enzyme activity and therefore lower 
baseline levels of active Vitamin K-dependent clotting 
factors.33 These individuals would already be predisposed to 
spontaneous bleeding, and the addition of an “average” 
warfarin dose could push these individuals to supra-therapeutic 
INR levels. In a study by Sconce et al14, those with the 
homozygous variant mutations for VKORC1 3673 required 
only 2.23 mg/day warfarin versus the heterozygote variants 
averaging 3.83 mg/day and homozygous wild type averaging 
4.53 mg/day.
It is interesting to note that at least 68% of our patient 
population at risk for warfarin adverse effects had at least one 
warfarin sensitivity mutation of either CYP2C9 or VKORC1. 
Further, 58.8% had the VKORC1 mutation, which is known to 
be the most clinically significant contribution to warfarin 
sensitivity. This means that at least this 58% of our population 
would likely have benefited from a decreased initial warfarin 
dose than standard algorithms would have prescribed. 
Although our study specifically looked at VTE patients, we 
would expect to find similar mutations rates for all patients 
needing warfarin anticoagulation (atrial fibrillation, prosthetic 
heart values, pre-op patients, etc.). However, mutation rates 
for these specific populations need further testing before such 
assumptions can be verified. Our pilot study also showed that 
testing for warfarin sensitivity SNPs in the ED for patients 
prior to starting the medication may be feasible once more 
rapid testing is widely available. The allele frequencies of the 
VKORC1, CYP2C9*2, and CYP2C9*3 in our population 
were high enough to warrant testing for these mutations. 
Our study also helped add to the knowledge of VKORC1 
3673, CYP2C9*2, and CYP2C9*3 allele frequencies in a 
Hispanic-American population. Review of the literature 
revealed only three prior studies looking at Hispanic CYP2C9 
allele frequencies and one additional study to include 
VKORC1 allele frequencies in a Hispanic population.9-12 Two 
studies looked at South American populations and found allele 
frequencies of 4.8% for CYP2C9*2 and 3.0% for CYP2C9*3 
in 778 Bolivians and VKORC1 3673 frequencies of 45% for 
191 genetically isolated Columbians.9,11 Another study looked 
at 434 Hispanic-Americans and found allele frequencies of 
12.0% for CYP2C9*2 and 3.4% for CYP2C9*3.12 Finally, one 
study specifically looked at the allele frequencies differences 
between Mexican-Americans and Spaniards and found that 
196 Mexican-Americans had allele frequencies of 8.0% for 
CYP2C9*2 and 6.0% for CYP2C9*3; these frequencies were 
statistically different from the 16.0% for CYP2C9*2 and 
10.0% for CYP2C9*3 for Spaniards and pointed to the need 
for optimizing dosing based on Hispanic-American allele 
frequency data instead of applying European or Caucasian 
allele frequencies to Hispanic populations.10 The allele 
frequencies for our Hispanic population of 5.73% for 
CYP2C9*2, 3.28% for CYP2C9*3, and 46.64% for VKORC1 
3673 were similar to these other studies. From what is known 
of these warfarin SNPs in the Hispanic population, the allele 
frequencies most closely align with the Caucasian population. 
However, it should be noted that the Hispanic population 
tends to have slightly lower CYP2C9*2 and higher VKORC1 
3673 frequencies than the Caucasian population (Table 3). The 
wide inter-ethnic variability of allele frequencies for 
CYP2C9*2, CYP2C9*3, and VKORC1 3673 has previously 
been shown to explain much of the inter-ethnic variability in 
warfarin dosing.8,6,12,26,28
Finally, a recent multi-national NIH funded study published 
in the New England Journal of Medicine34 has used data on over 
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4,000 patients to establish a genetics-based dosing algorithm for 
warfarin. This algorithm uses basic patient characteristics, such 
as age, gender, and ethnicity, along with the patient’s known 
CYP2C9 and VKORC1 SNPs to more accurately predict a 
patient’s warfarin maintenance dose than standard dosing 
algorithms. While the algorithm has been validated, it is not yet 
known if using this new pharmacogenetic-based algorithm will 
decrease the cost of warfarin treatment and dosing titration as 
well as the drug’s adverse effects.
A number of small studies have indicated a decreased 
incidence of warfarin adverse events when genetics-based 
dosing algorithms are used in initiating warfarin therapy 
versus standard dosing algorithms.35,36 However, a few other 
studies have failed to show a statistical difference in adverse 
events and outcomes between genetic-based and standard 
algorithms.37 Larger randomized controlled studies will be 
needed to determine the superior algorithm and the cost-
benefit analysis of using pharmacogenetic-based warfarin 
dosing. Also, while a few of the small randomized controlled 
studies that have been completed have boasted a quick turn-
around time of genotyping in 1-4 hours, these studies still 
used research laboratories for testing.24,35-37 Clinical laboratory 
and point of care testing for both the CYP2C9 and VKORC1 
SNPs are being developed and will likely reach mainstream 
markets in a year or two. Once this occurs we are likely to see 
increased use of pharmacogenetic-based warfarin dosing. 
CONCLUSION
Knowledge of a patient’s warfarin sensitivity SNPs 
is likely to benefit emergency medicine by decreasing 
the number of inpatient admissions for warfarin titration 
and decreasing ED visits for warfarin adverse events.  
Practitioners can well imagine a clinical scenario in which 
a patient is low risk for VTE complications but high risk 
for anticoagulation complications, for example the elderly.  
Knowledge of warfarin sensitivity SNPs would allow the 
emergency physician to tailor the warfarin dose specifically 
for the patient, thereby decreasing the risk of elevated INR 
and bleeding. The patient might then be safely discharged 
home with outpatient follow up instead of admission. As 
technology for genetic testing improves, a patient’s warfarin 
susceptibility SNPs might become part of an emergency 
physician’s evaluation and treatment of VTE. Our pilot study 
shows that allele frequencies of target warfarin sensitivity 
SNPs are frequent enough to make personalized warfarin 
dosing in the ED feasible.
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